Naloxone Shortage: What Providers and Prescribers Need to Know in 2026

Naloxone Shortage: A Provider Briefing for 2026

As a prescriber or healthcare provider, you've likely encountered the downstream effects of Naloxone supply fluctuations — whether it's patients struggling to fill prescriptions, EMS departments rationing injectable vials, or pharmacies reporting inconsistent stock of specific formulations.

This briefing covers the current state of Naloxone availability in 2026, what's changed since the OTC transition, and practical steps you can take to ensure your patients have access to this life-saving medication.

Timeline: How We Got Here

2018-2022: Injectable Shortages Emerge

Injectable Naloxone (0.4 mg/mL vials) first appeared on the FDA Drug Shortage list in 2018 as demand surged in response to the escalating opioid epidemic. Hospitals, EMS agencies, and correctional facilities competed for limited supply. During this period, nasal spray (Narcan 4 mg) was available by prescription and through community distribution programs, but access was inconsistent.

2023: The OTC Watershed

In March 2023, the FDA approved Narcan 4 mg nasal spray for over-the-counter sale — a landmark decision. By September 2023, OTC Narcan was on pharmacy shelves nationwide. RiVive (3 mg nasal spray) followed as a second OTC option. Simultaneously, the FDA approved Nalmefene (Opvee), a longer-acting opioid antagonist nasal spray, expanding the reversal agent toolkit.

2024-2025: Improved Access, Persistent Gaps

OTC availability significantly improved community-level access. However, injectable formulations continued to experience intermittent shortages. Rural and underserved areas remained disproportionately affected. The proliferation of illicit Fentanyl — and its increasing potency — drove clinical discussions about whether standard 4 mg nasal doses were sufficient, leading to greater interest in Kloxxado (8 mg) and Zimhi (5 mg IM).

2026: Current State

OTC nasal spray supply is broadly stable. Injectable vials remain subject to periodic supply constraints. The market now includes multiple formulations and an alternative agent (Nalmefene), giving providers more options than at any point in the epidemic.

Prescribing Implications

OTC vs. Prescription: What Still Needs an Rx?

Understanding the prescribing landscape is critical for guiding patients appropriately:

• No prescription needed: Narcan 4 mg nasal spray, RiVive 3 mg nasal spray
• Prescription required: Kloxxado 8 mg nasal spray, Zimhi 5 mg auto-injector, Nalmefene (Opvee) nasal spray, Injectable Naloxone vials

For patients who can access OTC options, a prescription may still be beneficial: it enables insurance billing (often reducing out-of-pocket cost to $0), creates documentation in the medical record, and allows you to specify higher-dose formulations when clinically appropriate.

When to Prescribe Higher-Dose Formulations

Consider prescribing Kloxxado (8 mg) or Zimhi (5 mg IM) for patients at higher risk of exposure to synthetic opioids, including:

• Patients with known Fentanyl use or exposure risk
• Patients prescribed high-dose opioid therapy (≥50 MME/day)
• Patients with history of overdose requiring multiple Naloxone doses
• Household contacts of individuals using illicit opioids

Co-Prescribing Recommendations

The CDC and most state guidelines recommend co-prescribing Naloxone with opioid prescriptions, particularly for patients on ≥50 morphine milligram equivalents (MME) per day, patients with concurrent benzodiazepine prescriptions, or patients with a history of substance use disorder. Documenting Naloxone co-prescribing supports quality measures and can be tracked via EHR.

Current Availability Picture

What's Available and Where

• Narcan 4 mg nasal spray (OTC): Widely available at chain pharmacies, grocery store pharmacies, and online retailers
• RiVive 3 mg nasal spray (OTC): Available but with smaller distribution footprint than Narcan
• Kloxxado 8 mg nasal spray (Rx): Available at most chain pharmacies; may require ordering at independent pharmacies
• Zimhi 5 mg auto-injector (Rx): Less widely stocked; specialty pharmacies and larger chains more reliable
• Opvee/Nalmefene (Rx): Growing availability; not yet universally stocked
• Injectable vials (Rx): Subject to intermittent shortages; hospital and EMS supply chains most affected

To help patients locate specific products, direct them to Medfinder for Providers, which offers real-time pharmacy stock checking.

Cost and Access Considerations

Patient Out-of-Pocket Costs

• OTC Narcan: $35-$50 for 2-pack (no insurance billing)
• OTC RiVive: $25-$40 for 2-pack
• Kloxxado (Rx): $75-$120 cash; often $0-$25 with insurance
• Zimhi (Rx): $300-$500 cash; most insured patients pay $0-$50
• Opvee (Rx): $60-$100 cash

Insurance and Coverage

Most commercial plans, Medicaid (all 50 states), and Medicare Part D cover prescription Naloxone formulations. Prior authorization is rarely required. Prescribing (rather than directing to OTC) unlocks insurance coverage and may be more cost-effective for patients.

Free Distribution Channels

Ensure your patients are aware of free Naloxone programs:

• State health department distribution programs
• NEXT Distro (naloxoneforall.org) — free mail-order Naloxone
• Local harm reduction organizations and syringe service programs
• Community health center distribution events

Tools and Resources for Your Practice

• Medfinder for Providers — Real-time pharmacy stock lookup to help patients find Naloxone
• SAMHSA Opioid Overdose Prevention Toolkit — Clinical guidance and patient education materials
• Prescribe to Prevent (prescribetoprevent.org) — Evidence-based resources for Naloxone co-prescribing
• CDC Clinical Practice Guideline for Prescribing Opioids — Updated co-prescribing recommendations

Looking Ahead

Several developments may further improve Naloxone access in the near future:

• Generic OTC options — Additional generic nasal spray products are expected to enter the market, driving prices down further
• Expanded standing orders — More states are broadening pharmacist authority to dispense all Naloxone formulations without an individual prescription
• Higher-dose products — Continued development of formulations designed to counter increasingly potent synthetic opioids
• Federal funding — Ongoing SAMHSA and state opioid response grants support community distribution infrastructure

Final Thoughts

Naloxone access in 2026 is better than it has ever been — but gaps persist, particularly for injectable formulations and in underserved communities. As a provider, you play a critical role in ensuring your patients have access by co-prescribing when appropriate, directing them to available formulations, and connecting them with free distribution programs and tools like Medfinder.

For patient-facing information to share with your practice, see our companion posts on what patients need to know about the Naloxone shortage and how to find Naloxone in stock.